EverHint — Pullback Plays October 27, 2025
October 27, 2025
How we frame a “pullback play”
We want leaders pressing back toward support (we track the 21-day) while staying near 52-week highs and holding short-term relative strength. We prefer orderly dips or tight pauses over breakdowns.
Top Setup
COGT — Cogent Biosciences (Healthcare)
- Price: $16.20
- % of 52-wk High: 97.77% (still near highs)
- RS(21): 0.105 (positive)
- Volume Thrust: 1.46 (constructive, not overheated)
- 21-DMA: $15.55 → +4.18% above the 21-day (close enough to watch for a tag or tight flag)
- Short-term momentum: R10_2 −0.084 (minor cool-off), R21_3 +0.049 (trend still positive)
Why it’s on the list:
COGT remains in a strong primary uptrend but has cooled modestly over the last 10 sessions, keeping it close enough to the 21-DMA to make a buy-the-dip or breakout-through-tightness setup viable if the tape cooperates.
Fresh context (recent headlines):
- FDA Breakthrough Therapy for lead asset bezuclastinib (Oct 20). (Cogent Bio Investors)
- New KRAS(ON) program data presented at the AACR-NCI-EORTC conference (Oct 24/27). (Cogent Bio Investors)
How we’d stalk it (not advice):
- Patience > chase. Ideal is a tight, low-volume drift closer to ~$15.6–$15.9 (near the 21-DMA) or a brief undercut that reclaims the line.
- If strength persists without a dip, we’d want to see range contraction and higher lows first.
Risk checks:
Biotech is catalyst-driven; headline risk is real. Keep risk tight if trading the setup around the 21-DMA and reassess if price loses the line on volume.
Quick Notes on the Day’s Screen
- Count of qualifying names: 1
- Tilt: Healthcare leadership continued to show up in our criteria; many tech/AI leaders were still extended well above the 21-DMA, so they didn’t qualify as true “pullbacks” today.
Independent research. No hype, no pumps, no paid promotions — just clean, data-driven setups and how we’d frame them.